IONS
$70.99-0.33 (-0.46%)
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Recent News
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best growth stocks to buy according to billionaires. As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street. Based on 21 analyst targets, the average price target stood at $89.00, with a high target of $110.00 and a low target […]
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story
Ionis Pharmaceuticals received FDA Priority Review for its supplemental New Drug Application for olezarsen, targeting severe hypertriglyceridemia and reduction of acute pancreatitis risk. The company is presenting new Phase 3 data for DAWNZERA, its RNA targeted therapy for hereditary angioedema, at a major medical conference. These updates highlight important clinical and regulatory milestones for Ionis and patients living with serious rare conditions. Ionis Pharmaceuticals, listed as...